Coviu and ResApp Complete Initial ResAppDx-EU Integration

View printer-friendly version Brisbane, Australia, 30 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Coviu, Australia’s leading...

ResApp Builds European Market Presence

View printer-friendly version Health economic evaluations to be performed at multiple UK hospitals Significant interest in triaging COVID-19 patients using ResAppDx-EU Director, Sales and Marketing (Europe) appointed Brisbane, Australia, 26 March 2020 — ResApp...

Update on US FDA De Novo Classification Request

View printer-friendly version Brisbane, Australia, 11 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that the US Food and...

Direct-to-Consumer Product Update

View printer-friendly version Brisbane, Australia, 11 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provided an update on its...